Angiotropic large cell lymphoma presenting as intestinal obstruction. 2008

A M Quadri, and S Sylvester, and S Verma, and D Bareford, and R T Spychal, and E L Jones, and R Ganesan

UI MeSH Term Description Entries
D007415 Intestinal Obstruction Any impairment, arrest, or reversal of the normal flow of INTESTINAL CONTENTS toward the ANAL CANAL. Intestinal Obstructions,Obstruction, Intestinal
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009389 Neovascularization, Pathologic A pathologic process consisting of the proliferation of blood vessels in abnormal tissues or in abnormal positions. Angiogenesis, Pathologic,Angiogenesis, Pathological,Neovascularization, Pathological,Pathologic Angiogenesis,Pathologic Neovascularization,Pathological Angiogenesis,Pathological Neovascularization
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D015415 Biomarkers Measurable and quantifiable biological parameters (e.g., specific enzyme concentration, specific hormone concentration, specific gene phenotype distribution in a population, presence of biological substances) which serve as indices for health- and physiology-related assessments, such as disease risk, psychiatric disorders, ENVIRONMENTAL EXPOSURE and its effects, disease diagnosis; METABOLIC PROCESSES; SUBSTANCE ABUSE; PREGNANCY; cell line development; EPIDEMIOLOGIC STUDIES; etc. Biochemical Markers,Biological Markers,Biomarker,Clinical Markers,Immunologic Markers,Laboratory Markers,Markers, Biochemical,Markers, Biological,Markers, Clinical,Markers, Immunologic,Markers, Laboratory,Markers, Serum,Markers, Surrogate,Markers, Viral,Serum Markers,Surrogate Markers,Viral Markers,Biochemical Marker,Biologic Marker,Biologic Markers,Clinical Marker,Immune Marker,Immune Markers,Immunologic Marker,Laboratory Marker,Marker, Biochemical,Marker, Biological,Marker, Clinical,Marker, Immunologic,Marker, Laboratory,Marker, Serum,Marker, Surrogate,Serum Marker,Surrogate End Point,Surrogate End Points,Surrogate Endpoint,Surrogate Endpoints,Surrogate Marker,Viral Marker,Biological Marker,End Point, Surrogate,End Points, Surrogate,Endpoint, Surrogate,Endpoints, Surrogate,Marker, Biologic,Marker, Immune,Marker, Viral,Markers, Biologic,Markers, Immune
D016403 Lymphoma, Large B-Cell, Diffuse Malignant lymphoma composed of large B lymphoid cells whose nuclear size can exceed normal macrophage nuclei, or more than twice the size of a normal lymphocyte. The pattern is predominantly diffuse. Most of these lymphomas represent the malignant counterpart of B-lymphocytes at midstage in the process of differentiation. Diffuse Large B-Cell Lymphoma,Diffuse, Large B-Cell, Lymphoma,Histiocytic Lymphoma, Diffuse,Lymphoma, Histiocytic, Diffuse,Diffuse Large-Cell Lymphoma,Histiocytic Lymphoma,Large Lymphoid Lymphoma, Diffuse,Large-Cell Lymphoma, Diffuse,Lymphoma, Diffuse Large-Cell,Lymphoma, Histiocytic,Lymphoma, Large Cell, Diffuse,Lymphoma, Large Lymphoid, Diffuse,Lymphoma, Large-Cell, Diffuse,Diffuse Histiocytic Lymphoma,Diffuse Histiocytic Lymphomas,Diffuse Large B Cell Lymphoma,Diffuse Large Cell Lymphoma,Diffuse Large-Cell Lymphomas,Histiocytic Lymphomas,Large Cell Lymphoma, Diffuse,Lymphoma, Diffuse Histiocytic,Lymphoma, Diffuse Large Cell
D051925 CD79 Antigens Components of the B-cell antigen receptor that function in B-cell antigen receptor heavy chain transport to the PLASMA MEMBRANE. They are expressed almost exclusively by B-LYMPHOCYTES and are markers for B-cell NEOPLASMS. Antigens, CD79,Antigens, CD79a,Antigens, CD79b,CD79a Antigens,CD79b Antigens,B-Cell Antigen Receptor Complex Associated Protein Beta-Chain,CD79 Antigen,CD79a Antigen,CD79b Antigen,IgM-Alpha Component,Igbeta Antigen,Immunoglobulin-Associated Alpha Protein,Immunoglobulin-Associated Beta Protein,Antigen, CD79,Antigen, CD79a,Antigen, CD79b,Antigen, Igbeta,B Cell Antigen Receptor Complex Associated Protein Beta Chain,IgM Alpha Component,Immunoglobulin Associated Alpha Protein,Immunoglobulin Associated Beta Protein

Related Publications

A M Quadri, and S Sylvester, and S Verma, and D Bareford, and R T Spychal, and E L Jones, and R Ganesan
February 1996, Human pathology,
A M Quadri, and S Sylvester, and S Verma, and D Bareford, and R T Spychal, and E L Jones, and R Ganesan
July 1988, Thorax,
A M Quadri, and S Sylvester, and S Verma, and D Bareford, and R T Spychal, and E L Jones, and R Ganesan
April 1999, The American journal of the medical sciences,
A M Quadri, and S Sylvester, and S Verma, and D Bareford, and R T Spychal, and E L Jones, and R Ganesan
November 2002, American journal of hematology,
A M Quadri, and S Sylvester, and S Verma, and D Bareford, and R T Spychal, and E L Jones, and R Ganesan
March 1995, Cancer,
A M Quadri, and S Sylvester, and S Verma, and D Bareford, and R T Spychal, and E L Jones, and R Ganesan
July 2000, Human pathology,
A M Quadri, and S Sylvester, and S Verma, and D Bareford, and R T Spychal, and E L Jones, and R Ganesan
June 2004, Journal of experimental & clinical cancer research : CR,
A M Quadri, and S Sylvester, and S Verma, and D Bareford, and R T Spychal, and E L Jones, and R Ganesan
February 1995, Southern medical journal,
A M Quadri, and S Sylvester, and S Verma, and D Bareford, and R T Spychal, and E L Jones, and R Ganesan
January 1992, Clinical neurology and neurosurgery,
A M Quadri, and S Sylvester, and S Verma, and D Bareford, and R T Spychal, and E L Jones, and R Ganesan
April 1988, Postgraduate medical journal,
Copied contents to your clipboard!